Furthermore, in patients with X-linked myotubular myopathy, the investigational therapeutic MTM1 (myotubularin) named AT132 using an AAV8 resulted in four deaths showing liver dysfunction from 3–4 weeks after receiving AT132. This evidence concerns the gene MTM1 and X-linked myotubular myopathy.